Cryoport, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Cryoport reported Q2 2026 revenue of $49.0M (up 8% YoY from $45.5M), with Life Sciences Services up 15% to $28.0M and BioStorage/BioServices up 25% to $5.6M. The company achieved positive adjusted EBITDA of $0.4M in Q2 2026 (vs. negative $0.9M in Q2 2025), a key profitability milestone. Cash position stands at $396.7M; the company supports 779 clinical trials and 22 approved cell/gene therapies as of June 30, 2026.
Why this rating
Profitability inflection point material for biotech logistics company; revenue growth modest relative to $400M market cap; adjusted EBITDA positive is operational milestone but absolute earnings still negative.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.